SEPTIN9 and urinary bladder cancer: As shown in Table 3, SEPT9 is exceptionally specific regarding colorectal cancer when compared to detecting NCCs: only a few plasma samples from liver cancer (2 out of 8 samples), lung cancer (4 out of 13) and bladder cancer (4 out of 19) patients were positive for the marker.